Treating HER2+ Metastatic Breast Cancer: Caitlin’s Story

Sara A. Hurvitz, M.D., describes the subtypes, staging and grading of breast cancer.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her initial impression of when she was diagnosed.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, describes her experience learning about the surplus of treatment options and how she overcame her initial apprehension.

Sara A. Hurvitz, M.D., reviews the history of HER2+ breast cancer and the progressive research that has been done in this disease.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares the hope she had after progression because of the ongoing research for HER2+ breast cancer, and Sara A. Hurvitz, M.D., reviews the drug regimens available in this realm.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, shares her goals of treatment after progression of disease.

Sara A. Hurvitz, M.D., reviews the advances in HER2+ metastatic breast cancer that have been made over the past decade.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses how her quality of life has been since she began taking tucatinib with chemotherapy.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, discusses the learning curve of taking an oral medication, tucatinib, in combination with chemotherapy, and Sara A. Hurvitz, M.D., reviews methods for medication adherence.

Caitlin Flanagan, a patient with HER2+ metastatic breast cancer, and Sara A. Hurvitz, M.D., discuss treatment approaches and modifications during the COVID-19 pandemic.